49 terminated. 49 Phase 2, 16 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 49 | Terminated 49 |
| Phase 1 | 16 | Terminated 16 |
| Phase 3 | 2 | Terminated 2 |
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors Surufatinib, Placebo - Pancreatic Neuroendocrine Tumor | Phase 2 | Terminated | Changhai Hospital | 6 | 2024-06-17 | 2026-06-11 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Testing Obeticholic Acid for Familial Adenomatous Polyposis Biopsy Procedure, Biospecimen Collection, Gastrointestinal Endoscopy - Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2023-01-19 | 2026-05-14 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors TNG908 - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 110 | 2022-03-23 | 2026-04-15 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) THOR-707, Pembrolizumab - Pleural Mesothelioma, Non-small Cell Lung Cancer | Phase 2 | Terminated | Sanofi | 106 | 2021-09-23 | 2025-10-02 |
| Neoadjuvant PRRT With Y-90-DOTATOC in pNET peptide receptor radionuclide therapy with Y-90-DOTATOC - Pancreatic Neuroendocrine Tumor | Phase 2 | Terminated | European Institute of Oncology | 11 | 2020-09-15 | 2024-11-20 |
| Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Mithramycin - Esophageal Neoplasms, Lung Neoplasms | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2019-08-08 | 2022-04-05 |
| A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies BAY94-9343 (Anetumab ravtansine) - Solid Tumors | Phase 2 | Terminated | Bayer | 9 | 2019-06-03 | 2023-08-04 |
| A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Rebastinib, Carboplatin - Locally Advanced or Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Deciphera Pharmaceuticals, LLC | 70 | 2019-01-02 | 2024-12-27 |
| Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma LMB-100, Pembrolizumab - Mesothelioma | Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2018-12-04 | 2021-12-02 |
| Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma Nivolumab, Ramucirumab - Mesothelioma, Malignant | Phase 2 | Terminated | Arkadiusz Z. Dudek, MD | 34 | 2018-06-26 | 2024-05-14 |
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2018-04-11 | 2023-05-31 |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma Nintedanib, Placebo - Malignant Pleural Mesothelioma | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 37 | 2018-02-04 | 2025-09-19 |
| Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma Anti-PD-1 antibody, DC-CIK Immunotherapy, Thermotron RF-8EX - Cancer, Mesothelioma, Malignant | Phase 1 / Phase 2 | Terminated | Capital Medical University | 10 | 2017-12-01 | 2024-02-07 |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies INCAGN01876, Epacadostat, Pembrolizumab - Advanced Malignancies, Metastatic Cancer | Phase 1 / Phase 2 | Terminated | Incyte Biosciences International Sàrl | 10 | 2017-11-21 | 2021-07-22 |
| Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma pevonedistat, Pemetrexed and cisplatin - Mesothelioma | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 9 | 2017-10-05 | 2024-05-23 |
Showing 20 of 49. Sign in to see all of them.
Mesothelioma, Malignant (21) · Mesothelioma (20) · Carcinoma, Non-Small-Cell Lung (11) · Esophageal Neoplasms (9) · Adenoma, Islet Cell (6) · Glucagonoma (6) · Insulinoma (6) · Lung Neoplasms (6) · Neoplasms (6) · Somatostatinoma (6) · Breast Neoplasms (5) · Carcinoma, Islet Cell (5) · Colorectal Neoplasms (5) · Gastrinoma (5) · Neoplasm Metastasis (5)
Neoplasms by Histologic Type (48) · Neoplasms, Glandular and Epithelial (48) · Neoplasms (43) · Neoplasms by Site (40) · Neoplasms, Mesothelial (37) · Lung Diseases (30) · Respiratory Tract Diseases (30) · Respiratory Tract Neoplasms (30) · Thoracic Neoplasms (30) · Lung Neoplasms (24) · Digestive System Diseases (21) · Digestive System Neoplasms (21) · Pleural Neoplasms (21) · Mesothelioma (18)
Pemetrexed (8) · Cisplatin (7) · pembrolizumab (7) · Cyclophosphamide (3) · Everolimus (3) · Bevacizumab (2) · Carboplatin (2) · Leucovorin (2) · Plicamycin (2) · aldesleukin (2) · defactinib (2) · fludarabine (2) · nintedanib (2) · ARQ 197 (1) · Automobiles (1)
National Cancer Institute (NCI) (8) · Dana-Farber Cancer Institute (2) · Verastem, Inc. (2) · Aduro Biotech, Inc. (1) · Aminex Therapeutics, Inc. (1) · Arkadiusz Z. Dudek, MD (1) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · Boehringer Ingelheim (1) · Burzynski Research Institute (1) · Capital Medical University (1) · Changhai Hospital (1) · Columbia University (1) · Deciphera Pharmaceuticals, LLC (1) · ECOG-ACRIN Cancer Research Group (1)
United States (39) · France (8) · Italy (8) · Australia (6) · United Kingdom (6) · Canada (5) · Belgium (4) · Germany (4) · Japan (4) · Poland (4) · Spain (4) · Argentina (3) · Netherlands (3) · Sweden (3) · Chile (2)
David S Schrump, M.D. (3) · Alain Tremblay, MD (1) · Arkadiusz Dudek, MD (1) · Arkadiusz Z Dudek, MD (1) · Biagio Ricciuti, MD (1) · David J. Sugarbaker, MD (1) · Eduardo Vilar-Sanchez (1) · Emily K. Bergsland, MD (1) · Eric Raymond, Professor (1) · Gang Jin, Doctor (1) · Hagop Youssoufian (1) · Hedy Kindler (1) · Jianming Xu, Doctor (1)
PMID 30785827, PMID 31103412, PMID 38046376, PMID 39756156, PMID 39863139
2014 (1), 2019 (1), N01CM00071 (1), P30CA014599 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), U01CA076576 (1), U10CA021115 (1), UG1CA242609 (1)